Skip to main content
Premium Trial:

Request an Annual Quote

AccuraGen Raises $40M in Series B Financing

NEW YORK (GenomeWeb) – Liquid biopsy startup AccuraGen said today that it has raised $40 million in a Series B financing round to support development and commercialization of its liquid biopsy technology, dubbed Firefly.

Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford-StartX Fund, and Nan Fung Capital, along with Series A investors, participated in the round.

In addition, the company said that it had appointed Dan Zabrowski, head of sequencing and tissue diagnostics at Roche, and Junson Capital CEO Kevin Liu to its board.

AccuraGen, which has a 20-member team headquartered in Menlo Park, California and also has a 45-member clinical team in Shanghai, described its technology earlier this year at the Molecular Medicine Tri-Conference in San Francisco. AccuraGen said then that it was developing a 61-gene NGS-based test to analyzing circulating tumor DNA and conducting clinical research studies with collaborators in China.

Last year, the company raised $6.9 million in a Series A round led by Decheng Capital and Denlux Capital, along with Yifang Group Holdings Limited and WS Investment.